Hospital
Banner Health
Banner Health was paid $55.03M by Medicaid between Jan 2018 and Dec 2024, across 293 billing codes. Its largest line is 99285, emergency room visit (most serious) — 23% of everything it billed.
33Billing provider infoBANNER HEALTH
CASA GRANDE, AZ 85122
CASA GRANDE, AZ 85122
33aNPI1003232976assigned 03/14/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$55.03M
24GClaims1,290,012
24DCodes billed293
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#9 of 78
Median peer was paid$12.21M
This provider vs. median4.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 234,242 | $10.09M | |
| 2019 | 207,982 | $9.89M | |
| 2020 | 136,767 | $6.79M | |
| 2021 | 160,914 | $6.96M | |
| 2022 | 193,212 | $7.26M | |
| 2023 | 193,951 | $7.41M | |
| 2024incomplete | 162,944 | $6.63M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 23% | 36,843 | 32,277 | $12.85M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 45,686 | 41,325 | $12.20M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 15% | 11,460 | 10,685 | $8.21M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 31,993 | 30,052 | $7.57M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.7% | 4,897 | 4,541 | $2.60M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 11,505 | 10,782 | $1.57M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.8% | 2,829 | 2,638 | $1.52M |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.6% | 3,837 | 3,562 | $1.41M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 11,940 | 10,784 | $1.24M |
| 47562 | 1.4% | 196 | 185 | $779K | |
| 70496 | 1.1% | 846 | 778 | $617K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,105 | 986 | $506K |
281 more codes
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,805 | $364K |
| 95811 | <1% | 408 | $280K | |
| 93971 | <1% | 1,945 | $238K | |
| G0378 | Hospital observation service, per hour | <1% | 14,738 | $236K |
| 72131 | <1% | 614 | $229K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 156 | $220K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,307 | $119K |
| 80053 | Comprehensive metabolic panel | <1% | 74,203 | $107K |
| 70486 | <1% | 1,241 | $106K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 359 | $94K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,329 | $92K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 324 | $89K |
| 49083 | <1% | 171 | $88K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 530 | $85K |
| 74174 | <1% | 85 | $82K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,946 | $81K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 35,811 | $68K |
| 70498 | <1% | 1,016 | $68K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 12,678 | $64K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,162 | $61K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,850 | $54K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 342 | $51K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 286 | $50K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 246 | $46K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,773 | $45K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 36,559 | $45K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 86 | $43K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 532 | $42K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,669 | $38K |
| 70491 | <1% | 111 | $38K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 8,143 | $36K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,341 | $35K |
| 97597 | <1% | 690 | $32K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,086 | $30K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 362 | $29K |
| 76642 | <1% | 369 | $27K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,564 | $25K |
| 77080 | <1% | 356 | $25K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 273 | $24K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 42 | $22K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,733 | $22K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 225 | $19K |
| 80320 | <1% | 6,857 | $17K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 30,718 | $16K |
| 99205 | Prolong outpt/office vis | <1% | 102 | $13K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,472 | $13K |
| 71045 | Radiologic examination, chest; single view | <1% | 23,373 | $13K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 166 | $11K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 13 | $11K |
| 76770 | <1% | 203 | $11K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,579 | $9K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,416 | $9K |
| 73130 | <1% | 2,383 | $9K | |
| 71250 | <1% | 308 | $9K | |
| 74178 | <1% | 32 | $9K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,552 | $9K |
| 76801 | <1% | 2,343 | $8K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 63 | $8K |
| 74018 | <1% | 2,000 | $8K | |
| 36430 | <1% | 144 | $8K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 14 | $8K |
| 93970 | <1% | 46 | $7K | |
| 96376 | <1% | 9,997 | $7K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 76,005 | $7K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 103 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,440 | $7K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 7,724 | $7K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,608 | $7K |
| 97161 | <1% | 495 | $6K | |
| 73610 | <1% | 2,222 | $6K | |
| 84484 | <1% | 29,797 | $5K | |
| 10060 | <1% | 123 | $5K | |
| 93880 | <1% | 92 | $5K | |
| 94762 | <1% | 7,209 | $5K | |
| 73030 | <1% | 2,447 | $5K | |
| 59025 | Fetal non-stress test | <1% | 199 | $5K |
| 87631 | <1% | 3,135 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 28 | $4K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 155 | $4K |
| 73110 | <1% | 1,563 | $4K | |
| 76536 | <1% | 68 | $4K | |
| J3490 | Unclassified drugs | <1% | 33,611 | $4K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 12 | $3K |
| 73562 | <1% | 2,668 | $3K | |
| 73630 | <1% | 2,639 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,652 | $3K |
| 88341 | <1% | 37 | $3K | |
| 73502 | <1% | 899 | $3K | |
| 81025 | <1% | 12,733 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 197 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 18,220 | $2K |
| 72192 | <1% | 16 | $2K | |
| 97162 | <1% | 135 | $2K | |
| 83880 | <1% | 5,101 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 138 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,753 | $2K |
| 36416 | <1% | 684 | $2K | |
| 83690 | <1% | 23,173 | $2K | |
| 72100 | <1% | 469 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 15,643 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,804 | $2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,753 | $1K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 390 | $1K |
| 73564 | <1% | 42 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,331 | $1K |
| 88342 | <1% | 703 | $1K | |
| 80329 | <1% | 1,275 | $1K | |
| 82947 | <1% | 26,289 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,578 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,635 | $1K |
| 73080 | <1% | 825 | $1K | |
| 72128 | <1% | 69 | $1K | |
| 84703 | <1% | 10,456 | $1K | |
| 81001 | <1% | 30,008 | $1K | |
| A9270 | Non-covered item or service | <1% | 45,900 | $914.08 |
| 82803 | <1% | 785 | $869.10 | |
| 85610 | <1% | 14,577 | $835.76 | |
| 87040 | <1% | 9,778 | $833.51 | |
| 80061 | Lipid panel | <1% | 456 | $807.14 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,665 | $793.20 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 17,410 | $763.66 |
| 86850 | <1% | 3,626 | $760.77 | |
| 83735 | <1% | 9,906 | $731.73 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 859 | $711.36 |
| 85379 | <1% | 2,693 | $670.53 | |
| 83605 | <1% | 11,221 | $658.19 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,434 | $649.61 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,446 | $645.33 |
| 81003 | <1% | 14,361 | $625.17 | |
| 84702 | <1% | 5,135 | $622.70 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 22,985 | $612.57 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 897 | $609.35 |
| C1769 | Guide wire | <1% | 287 | $594.20 |
| 76830 | Ultrasound, transvaginal | <1% | 812 | $574.36 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 31,284 | $557.69 |
| 0450 | Emergency room services | <1% | 13 | $550.14 |
| 82140 | <1% | 1,001 | $534.18 | |
| 90715 | <1% | 2,126 | $533.28 | |
| 85027 | <1% | 7,754 | $500.50 | |
| 82550 | <1% | 3,691 | $498.42 | |
| 86901 | <1% | 5,173 | $438.58 | |
| 87081 | <1% | 1,865 | $430.06 | |
| 85730 | <1% | 3,732 | $426.62 | |
| 97116 | <1% | 744 | $413.64 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 33,428 | $393.14 |
| J1815 | Injection, insulin, per 5 units | <1% | 5,922 | $388.30 |
| 12002 | <1% | 239 | $378.07 | |
| 87088 | <1% | 11,620 | $365.64 | |
| 73090 | <1% | 559 | $347.50 | |
| 73590 | <1% | 506 | $335.53 | |
| 96367 | <1% | 1,466 | $332.11 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,374 | $308.43 |
| 71101 | <1% | 72 | $275.94 | |
| 82565 | <1% | 180 | $272.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 10,889 | $241.82 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 649 | $224.87 |
| 87186 | <1% | 4,406 | $221.87 | |
| 73140 | <1% | 78 | $209.49 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 168 | $200.28 |
| 12001 | <1% | 793 | $180.70 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,342 | $165.14 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 406 | $162.94 |
| 87077 | <1% | 5,563 | $162.06 | |
| 88307 | <1% | 273 | $151.77 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 2,649 | $139.70 |
| 82270 | <1% | 334 | $135.91 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,714 | $130.52 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,116 | $129.70 |
| 72072 | <1% | 13 | $125.44 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 4,653 | $112.46 |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 50 | $112.21 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 220 | $112.16 |
| 82010 | <1% | 784 | $109.61 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,905 | $106.09 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 426 | $98.34 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,687 | $92.39 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 366 | $88.69 |
| 85055 | <1% | 1,957 | $84.62 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,103 | $78.69 |
| 87807 | <1% | 543 | $77.73 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,813 | $72.07 |
| 84132 | <1% | 1,263 | $69.07 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 399 | $65.15 |
| 86900 | <1% | 4,152 | $63.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,023 | $61.46 |
| 84145 | <1% | 258 | $57.57 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,041 | $55.75 |
| 86140 | <1% | 1,642 | $50.51 | |
| 94760 | <1% | 1,308 | $45.95 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 2,369 | $45.54 |
| 94664 | <1% | 505 | $45.24 | |
| 94644 | <1% | 113 | $44.91 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 165 | $44.21 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 833 | $39.87 |
| J2704 | Injection, propofol, 10 mg | <1% | 6,927 | $39.73 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,019 | $38.00 |
| 96368 | <1% | 465 | $37.63 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,145 | $35.12 |
| 87210 | <1% | 738 | $34.68 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,950 | $33.46 |
| 84100 | <1% | 875 | $29.62 | |
| 88304 | <1% | 1,059 | $29.05 | |
| 72040 | <1% | 71 | $24.97 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,231 | $24.96 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 634 | $24.49 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 278 | $23.41 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 368 | $23.38 |
| 36600 | <1% | 541 | $22.89 | |
| 74022 | <1% | 49 | $21.38 | |
| 73060 | <1% | 47 | $19.38 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,182 | $13.50 |
| 73552 | <1% | 27 | $11.72 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,134 | $11.61 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 812 | $11.25 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 31 | $10.34 |
| 85652 | <1% | 725 | $10.20 | |
| 84439 | <1% | 189 | $7.91 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,018 | $7.09 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 114 | $6.19 |
| J7999 | Compounded drug, not otherwise classified | <1% | 1,913 | $5.27 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 355 | $3.99 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,656 | $3.04 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 2,325 | $2.77 |
| 84520 | <1% | 149 | $2.52 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 581 | $1.25 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 870 | $1.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 937 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 102 | $0.00 |
| 85007 | 0% | 13 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 820 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 160 | $0.00 |
| 87275 | 0% | 43 | $0.00 | |
| 93041 | 0% | 48 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 294 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 92 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 170 | $0.00 |
| 84112 | 0% | 276 | $0.00 | |
| 97163 | 0% | 15 | $0.00 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 43 | $0.00 |
| 12011 | 0% | 241 | $0.00 | |
| 89051 | 0% | 14 | $0.00 | |
| 29125 | 0% | 34 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 208 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 15 | $0.00 |
| 86923 | 0% | 98 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 148 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 17 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 49 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 35 | $0.00 |
| 88313 | 0% | 69 | $0.00 | |
| 87075 | 0% | 84 | $0.00 | |
| 87254 | 0% | 51 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 17 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 109 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 66 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 1,168 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 673 | $0.00 |
| 87205 | 0% | 853 | $0.00 | |
| 87070 | 0% | 820 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 1,068 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 1,808 | $0.00 |
| 97010 | 0% | 769 | $0.00 | |
| 72170 | 0% | 59 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 377 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 802 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 88 | $0.00 |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 170 | $0.00 |
| 74420 | 0% | 27 | $0.00 | |
| 76870 | 0% | 41 | $0.00 | |
| 87147 | 0% | 220 | $0.00 | |
| 85018 | 0% | 207 | $0.00 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 35 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 41 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 122 | $0.00 |
| 90686 | 0% | 34 | $0.00 | |
| 97166 | 0% | 13 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 86 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 18 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 14 | $0.00 |
| 87276 | 0% | 43 | $0.00 | |
| J1836 | Injection, metronidazole, 10 mg | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHERPF, JOHN (CEO)